Jade Biosciences, Inc. (NASDAQ: JBIO) is a Healthcare company (Biotechnology) with a market capitalization of $979M. The Maz Rating grades it against the other companies in its sector.
Jade Biosciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $15.40, Jade Biosciences, Inc. trades at 2.4x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -42.8%, return on invested capital of -38.8% and a free cash flow yield of -13.3%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 16.03. Over the past 52 weeks the share price ranged from $11.02 to $28.00, with a beta of 1.45.
Jade Biosciences, Inc. does not currently pay a dividend.
4 Wall Street analyst ratings cover the stock: 4 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Jade Biosciences, Inc. (JBIO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 46.0% / 30% · Interest income / Revenue 462900000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 46.0% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 462900000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 46.0% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 462900000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 97.3% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 462900000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 97.8% / 33.33% · (Cash+Recv) / Total Assets 97.8% / 33.33% · Interest income / Revenue 462900000.0% / 5% | Fail |
No. As of September 2026, Jade Biosciences, Inc. (JBIO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Jade Biosciences, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 462900000.0% of each dividend: Jade Biosciences, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.